Monthly Prescribing Reference

Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis

Findings seen through 76 weeks of treatment for adolescents taking 15- or 30mg doses for moderate to severe atopic dermatitis. HealthDay News — Long-term treatment of adolescents with moderate to ...
Seeking Alpha

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic ...

NORTH CHICAGO, Ill., April 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study ...
MedPage Today

Managing IBD Patients Who Don't Respond, or Can't Tolerate, Upadacitinib

Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, is an emerging treatment for inflammatory bowel disease (IBD) and is increasingly used in clinical practice. Real-world data suggest ...
The American Journal of Managed Care

Upadacitinib Effective in Treating Patients With Moderate to Severe AD, Study Says

Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively. Upadacitinib was effective in treating patients ...
Healio

Long-term upadacitinib superior to methotrexate for rheumatoid arthritis

Please provide your email address to receive an email when new articles are posted on . Patients with RA treated with first-line upadacitinib over 5 years had greater reductions in disease activity vs ...
Healio

‘First of a new class’: FDA approves upadacitinib to treat giant cell arteritis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved upadacitinib to treat adults with giant cell arteritis. It is the second drug to be ...
Monthly Prescribing Reference

Upadacitinib Demonstrates Efficacy in Second Alopecia Areata Trial

Study 1 results showed 45.2% and 55.0% of patients treated with upadacitinib 15mg and 30mg, respectively, achieved the primary endpoint at 24 weeks compared with 1.5% of those receiving placebo.
Nasdaq

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) ...
MedPage Today on MSN

Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...
The American Journal of Managed Care

Upadacitinib Demonstrates Efficacy in RA Treatment Regardless of Patient’s Baseline CRP Levels

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.
clinicaladvisor.com

Upadacitinib Can Provide Symptom Relief for CD in the First Week

Upadacitinib can resolve Crohn disease symptoms within the first week, regardless of prior biologic therapy exposure. Patients with Crohn disease (CD) treated with upadacitinib 45 mg once daily can ...